ReviewCell communication and signaling : CCS2025
Review: Progress of the NLRP3 inflammasome in tumours and perspectives for cholangiocarcinoma.
Review in Cell communication and signaling : CCS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Mitochondrial Dysfunction as a Driver of Neurodegeneration in Parkinson's and Huntington's Disease: Molecular Insights and Emerging Interventions.Molecular neurobiology · 2026Review
- Dietary Antioxidants and Redox Signaling in Cancer Prevention: Mechanistic Insights and Metabolic Inflammation.Nutrients · 2026Review
- The Paradoxical Role of Pyroptosis in Gastrointestinal Cancers: From Molecular Mechanisms to Therapeutic Horizons.Biomedicines · 2026Review
- Integrating the hallmarks of cancer into autophagy: a perspective from underlying mechanisms to therapeutic strategies.Theranostics · 2026Review
- Inflammasome-associated pyroptosis and tumor angiogenesis in prostate cancer.Iranian journal of basic medical sciences · 2026Review
- Metrnl and macrophage polarization: role in skeletal muscle homeostasis and therapeutic potential.Frontiers in immunology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The NLRP3 inflammasome is a multi-protein complex that mediates intense inflammatory responses. Its activation and function are influenced by various factors, including the recognition of pathogen-associated molecular patterns and damage-associated molecular patterns, cellular stress responses, and metabolic disorders. Recent research has extensively studied the role of the NLRP3 inflammasome in tumors. Findings indicate that tumor cells and macrophages can regulate the activation of the NLRP3 inflammasome, promoting tumor development and progression. Conversely, the NLRP3 inflammasome can also exhibit anti-tumor effects through immune cells, such as dendritic cells. This has led to the development of treatment strategies, creating a comprehensive treatment system that includes sensitizers for radiotherapy and chemotherapy, inhibitors of the NLRP3 inflammasome pathway, and direct targeting of the NLRP3 inflammasome.Cholangiocarcinoma is a highly invasive and heterogeneous malignant tumor. Due to its non-specific symptoms, patients often present with advanced stages of the disease, and the mortality rate continues to rise annually. A deeper exploration of the mechanisms underlying cholangiocarcinoma's occurrence and development is essential for improving diagnosis and treatment strategies. The application of multi-omics analysis in cholangiocarcinoma research lays a foundation for understanding its pathogenesis and potential treatments. This article systematically reviews the latest advancements in NLRP3 inflammasome research, including its regulatory mechanisms, role in promoting tumor development, and effects in anti-tumor immunotherapy. Additionally, by summarizing the mechanisms involved in cholangiocarcinoma, we hypothesize that the NLRP3 inflammasome may play a significant role in the occurrence and development of cholangiocarcinoma. Therefore, we conduct a multi-angle analysis of the potential relationship between the two and propose a hypothesis model. The goal of this article is to explore the role of the NLRP3 inflammasome in tumors and its potential relationship with cholangiocarcinoma, offering new insights for research on the link between cholangiocarcinoma-related inflammation and the disease itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.